--- title: "Enlivex (ENLV) news: reverse split, delisting and offering" url: "https://aibio.space/companies/enlivex/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ENLV reverse split, delisting and offering news: Enlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split. Enlivex Ltd." --- ENLV Enlivex Ltd. NASDAQ · Israel # Enlivex (ENLV) news ENLV reverse split, delisting and offering news Listings · 2026-10-27 ## [Enlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split](https://aibio.space/news/enlivex-gets-nasdaq-delisting-notice-plans-appeal-1-16-reverse-split/) Because Enlivex already did a reverse split within the past 12 months, it is not entitled to a 180-day period to regain compliance. ## Latest Enlivex news 1. 2026-10-22 Listings [Enlivex announces 1-for-16 reverse share split effective October 27, 2026](https://aibio.space/news/enlivex-announces-1-16-reverse-share-split-effective-october-27-2026/) Issued shares will fall from 24,511,905 to about 1,531,995. The stock stays on the Nasdaq Capital Market under ENLV. 2. 2026-09-22 Financings [Enlivex terminates private placement of 66,666,667 shares payable in RAIN tokens](https://aibio.space/news/enlivex-terminates-private-placement-66-666-667-shares-payable-rain/) The agreement with the Rain Foundation was subject to shareholder approval. The company says it will not complete the placement or seek that approval. 3. 2026-08-11 Debt Financing [Enlivex amends $21.0 million Lind note and resets conversion price](https://aibio.space/news/enlivex-amends-21-0-million-lind-note-resets-conversion-price/) Enlivex deleted a market capitalization default from its Lind note and revised conversion and prepayment terms. Outstanding principal rose to $19.2 million. 4. 2026-05-15 Listings [Enlivex gets Nasdaq bid price notice, has until November 9, 2026](https://aibio.space/news/enlivex-gets-nasdaq-bid-price-notice-has-until-november-9-2026/) Nasdaq said the ordinary shares closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing or trading. ## Enlivex at a glance - **Ticker**: ENLV - **Listing**: NASDAQ - **Country**: Israel - **Cash, Dec 31, 2025**: $1.9 million ### Related companies - [NRGENE TECHNOLOGIES LTD](https://aibio.space/companies/nrgene-technologies/) TASE: NRGN - [Kamada](https://aibio.space/companies/kamada/) NASDAQ: KMDA - [Matricelf](https://aibio.space/companies/matricelf/) TASE: MTLF - [Pluri](https://aibio.space/companies/pluri/) NASDAQ: PLUR - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) AMEX: RGNT - [Polyrizon](https://aibio.space/companies/polyrizon/) NASDAQ: PLRZ - [Evogene](https://aibio.space/companies/evogene/) NASDAQ: EVGN - [Chemomab Therapeutics](https://aibio.space/companies/chemomab-therapeutics/) NASDAQ: CMMB ### Also on NASDAQ - [Quoin Pharmaceuticals](https://aibio.space/companies/quoin-pharmaceuticals/) QNRX - [Celcuity](https://aibio.space/companies/celcuity/) CELC - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) SRRK - [Oramed Pharmaceuticals](https://aibio.space/companies/oramed-pharmaceuticals/) ORMP - [908 Devices](https://aibio.space/companies/908-devices/) MASS - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM ## What Enlivex does Enlivex Ltd. describes itself as a quality longevity company focused on therapies designed to extend health span and improve quality of life. Its clinical development is currently focused on osteoarthritis, and its lead candidate, Allocetra, is a macrophage reprogramming therapy designed to restore immune balance and address inflammatory and degenerative conditions associated with aging. The company reported positive six-month efficacy data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra trial in patients with moderate to severe knee osteoarthritis. It is preparing a Phase IIb trial, and in March 2026 it received FDA clearance of its IND application for that trial. The company also runs a digital asset treasury anchored in the RAIN protocol, a decentralized predictions and options protocol built on the Arbitrum network. It launched the treasury reserve policy in November 2025, and it reported the fair value of that treasury as $606.781 million as of December 31, 2025. The company is based in Ness Ziona, Israel, and changed its name to Enlivex Ltd. in February 2026. | Product or program | What it is | Stage | |---|---|---| | Allocetra | Macrophage reprogramming therapy studied for knee osteoarthritis and age-related inflammatory conditions | positive Phase IIa data; Phase IIb being prepared; FDA IND clearance received March 2026 | | RAIN token | Token of a predictions and options protocol on Arbitrum, held in treasury | | Summarised from the company's [20-F filed Mar 25, 2026](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm). ## Enlivex annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$9.2 million](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | [$10.6 million](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | | Net income (loss) | [$1.24 billion](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | [-$15.0 million](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | | Cash from operations | [-$10.4 million](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | [-$13.0 million](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | | Cash and equivalents | [$1.9 million](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | | Short-term investments | | [$198,000](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $1.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Enlivex Did Enlivex do a reverse stock split? Our latest story on this, dated Oct 27, 2026: "Enlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/enlivex-gets-nasdaq-delisting-notice-plans-appeal-1-16-reverse-split/). Was Enlivex delisted? Our latest story on this, dated Oct 27, 2026: "Enlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/enlivex-gets-nasdaq-delisting-notice-plans-appeal-1-16-reverse-split/). Has Enlivex raised money recently? Our latest story on this, dated Sep 22, 2026: "Enlivex terminates private placement of 66,666,667 shares payable in RAIN tokens". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/enlivex-terminates-private-placement-66-666-667-shares-payable-rain/). What is the ticker symbol of Enlivex? Enlivex Ltd. trades under the ticker ENLV on NASDAQ. Where is Enlivex listed? Enlivex Ltd. is listed on NASDAQ. Our directory also records these other listings: LS:A119KH. What is the SEC CIK of Enlivex? The SEC Central Index Key (CIK) for Enlivex Ltd. is 1596812. Its filings are on SEC EDGAR. How many shares does Enlivex have outstanding? 237,381,498 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-25. Which country or territory is Enlivex listed under? Our directory records Enlivex Ltd. under Israel. What does Enlivex do? Our directory classifies Enlivex Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Enlivex? The ISIN recorded for Enlivex Ltd. is IL0011319527. Does aibio.space cover Enlivex? aibio.space lists Enlivex Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Enlivex incorporated? SEC records list its state or country of incorporation as L3. What does Enlivex develop? Enlivex Ltd. describes itself as a quality longevity company focused on therapies designed to extend health span and improve quality of life. Its clinical development is currently focused on osteoarthritis, and its lead candidate, Allocetra, is a macrophage reprogramming therapy designed to restore immune balance and address inflammatory and degenerative conditions associated with aging. What is Allocetra from Enlivex? Allocetra: Macrophage reprogramming therapy studied for knee osteoarthritis and age-related inflammatory conditions Stage: positive Phase IIa data; Phase IIb being prepared; FDA IND clearance received March 2026. What is RAIN token from Enlivex? RAIN token: Token of a predictions and options protocol on Arbitrum, held in treasury ## Investor discussion: Enlivex Members talk about Enlivex (ENLV). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Enlivex, newest first. Each line links the filing it comes from. 1. 2026-10-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026112690/ea030971201ex99-1.htm) 2. 2026-10-22 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026111752/ea030938901ex99-1.htm) 3. 2026-09-29 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026104752/ea030698901ex99-1.htm) 4. 2026-09-22 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026101973/ea030609201ex99-1.htm) 5. 2026-07-28 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026081993/ea029941801ex99-1.htm) 6. 2026-07-07 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026075756/ea029719501ex99-1.htm) 7. 2026-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026057782/ea029081501ex99-1.htm) 8. 2026-03-24 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026033240/ea028304501ex99-1.htm) 9. 2026-02-05 Distress Reported a bankruptcy filing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026012548/ea027570501ex99-1_enlivex.htm) 10. 2026-01-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390026006926/ea027363101ex99-1_enlivex.htm) 11. 2025-12-18 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390025123303/ea027011901ex99-1_enlivex.htm) 12. 2025-11-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1596812/000121390025113879/ea0266872-424b5_enlivex.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ENLV on TradingView](https://www.tradingview.com/symbols/NASDAQ-ENLV/). ## SEC filings and registration - **SEC name**: Enlivex Ltd. - **CIK**: 1596812 - **Industry (SIC)**: Finance Services (6199) - **US tickers**: ENLV (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 37 DEREH MENACHEM BEGIN ST., TEL AVIV - **Phone**: 972 (0) 3 7326616 - **Shares outstanding**: 237,381,498 as of 2025-12-31 (20-F filed 2026-03-25) - **Former names**: Enlivex Therapeutics Ltd.; Bioblast Pharma Ltd.; BIO BLAST PHARMA LTD. ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026111752/ea0309389-6k_enlivex.htm) filed 2026-10-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026110486/ea0308973-6k_enlivex.htm) filed 2026-10-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026104752/ea0306989-6k_enlivex.htm) filed 2026-09-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026103516/ea0306494-6k_enlivex.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026101973/ea0306092-6k_enlivex.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026087782/ea0301590-6k_enlivex.htm) filed 2026-08-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026083074/ea0299702-6k_enlivex.htm) filed 2026-07-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1596812/000121390026082559/ea0299617-6k_enlivex.htm) filed 2026-07-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001596812), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Enlivex Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ENLV, recorded under Israel. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Enlivex Ltd. - **Ticker**: ENLV - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Biotechnology - **ISIN**: IL0011319527 - **Other listed symbols**: LS:A119KH - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ENLV/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/enlivex/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Enlivex (ENLV) news: reverse split, delisting and offering", 2026-10-31, https://aibio.space/companies/enlivex/